• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2024

View Archived Issues
Illustration of Victor Ambros and Gary Ruvkun

Two win Nobel for microRNA work

Research into the regulation of gene expression experienced a significant breakthrough with the discovery of microRNA, small RNA molecules that do not code for proteins but control their translation. This finding has earned its discoverers – Victor Ambros and Gary Ruvkun – the 2024 Nobel Prize in Physiology or Medicine “for the discovery of microRNA and its role in post-transcriptional gene regulation.” Read More

Kurma closes €140M fund aimed at breakthrough research in Europe

Kurma Partners has announced the first closing of its Biofund IV at €140 million (US$154.5 million) and is pressing ahead to a final close of €250 million this time next year. The fund will make 16 to 20 investments, with half the money due to be invested in novel science that Kurma teases out of academic labs and the remainder in established VC-funded companies. The Paris-based firm is agnostic about which fields or disease areas it invests in and will prospect for breakthrough research anywhere in Europe. Read More
Illustration of digital syringe

Cancer Research UK funds University of Oxford research on vaccine to prevent ovarian cancer

Researchers at University of Oxford have been awarded funding by Cancer Research UK to develop a vaccine to prevent ovarian cancer. The team will receive up to £600,000 (US$784,000) for the study over the next 3 years to support lab research on Ovarianvax. Read More
Test-tubes_dropper2.png

Novel full MC4 receptor-specific nanobody described

The melanocortin MC4 receptor (MC4R), expressed in all brain regions, plays a relevant role in metabolism regulation and in the control of hunger and satiety. MC4R-specific agonist ligands such as setmelanotide have shown potential as antiobesity therapeutics, although reported off-target effects highlight the need for more specific compounds. Read More

Hyundai Pharmaceutical describes new SNF2L2 inhibitors

Hyundai Pharmaceutical Co. Ltd. has patented probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of cancer. Read More
Scanning electron micrograph of human RSV virions

LY6E and TCN2, new diagnostic biomarkers and therapeutic targets for RSV infection

Investigators at Wuxi No. 2 Peoples Hospital and affiliated organizations conducted studies to identify novel effective biomarkers for early-stage pediatric respiratory syncytial virus (RSV) infection (EPR). Read More

ANKRD1 as a therapeutic target in renal ischemia-reperfusion injury

Researchers from Renmin Hospital of Wuhan University have assessed the role of ankyrin repeat domain 1 (ANKRD1) in renal ischemia-reperfusion injury (IRI), which is the primary cause of acute kidney injury (AKI). Read More
Brain and encephalography

MRS-5474 exerts selective effect in epilepsy tissues

The adenosine A1 receptor (A1R) modulates ionic conductance in neuronal membrane and contributes to the anticonvulsant and neuroprotective role of the endogenous neuromodulator adenosine. Because A1Rs are present all throughout the body, the development of A1R modulation as antiseizure strategy may face difficulties such as side effects in the heart or other organs. Read More

Boehringer Ingelheim patents QPCT and QPCTL inhibitors

A Boehringer Ingelheim Pharma GmbH & Co. KG patent describes new phenylpiperidine derivatives acting as glutaminyl-peptide cyclotransferase (QPCT; QC) and glutaminyl-peptide cyclotransferase-like protein (QPCTL; IsoQC) inhibitors. Read More

FFA1 receptor agonists disclosed in Cascade Pharmaceuticals patent

Cascade Pharmaceuticals Inc. has synthesized benzoheterocyclic compounds acting as free fatty acid FFA1 receptor (GPR40) agonists reported to be useful for the treatment of diabetes. Read More
Brain and blood cells

Hi1a demonstrates neuroprotective activity in EAE mice

Khalifa University and The University of Queensland presented preclinical data for a novel acid-sensing ion channel 1 (ASIC1) inhibitor, Hi1a, evaluated in models of multiple sclerosis (MS). Read More

Shanghai Synergy and Zhejiang Huahai Pharmaceutical identify nucleoside prodrugs for cancer

Shanghai Synergy Pharmaceutical Sciences Co. Ltd. and Zhejiang Huahai Pharmaceutical Co. Ltd. have jointly disclosed new nucleoside prodrugs reported to be useful for the treatment of cancer. Read More

Aquinnah Pharmaceuticals discovers TDP-43 and tau aggregation inhibitors

Aquinnah Pharmaceuticals Inc. has identified new TAR DNA-binding protein 43 (TARDBP; TDP-43) aggregation and microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. Read More
Bacteria-in-petri-dishes.png

MEK1/2 inhibitor shows antibacterial and anti-inflammatory effects

It was hypothesized that the MEK1/2 inhibitor ATR-002 could reduce inflammation and clear Staphylococcus aureus infection during cystic fibrosis, thus potentially showing a dual effect. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 7, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 7, 2025.
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe